Pharmacy Diabetes

insulin-formulation_Mixtard30/70

Insulin (rys)

  • Mixtard 30/70: 1 mL suspension contains 100 international units’ soluble insulin. (rys)/isophane insulin (rys) in the ratio 30/70. The suspension is cloudy, white, and aqueous.
  • Insulin (rys) is produced by recombinant DNA technology using Saccharomyces cerevisiae.

  • The treatment of insulin-requiring diabetes.

https://www.pbs.gov.au/medicine/item/12255B-1426C-1763T-2062M

  • Mixtard 30/70 insulin is usually given once or twice daily when a rapid initial effect together with a more prolonged effect is required. An injection should be followed by a meal or snack containing carbohydrates within 30 minutes. Mixtard 30/70 is not to be administered intravenously. Insulin suspensions are not to be used in insulin infusion pumps.
  • Preparations containing cloudy insulins should be gently agitated by rolling between the hands (10 mL vials only) or gently shaken (Penfill and InnoLet only) before use to ensure the insulin is uniformly distributed throughout the liquid and the injection should be given immediately thereafter.
    Note: Diabetes MedsCheck with referral to healthcare team for education on injection technique, managing hypoglycaemia and blood glucose monitoring.
  • Use in renal impairment: Mixtard 30/70 can be used in renal impairment. As with all insulins, glucose monitoring should be intensified, and dosage adjustment should occur on an individual basis.
  • Use in liver impairment: Mixtard 30/70 can be used in hepatic impairment. As with all insulins, glucose monitoring should be intensified, and dosage adjustment should occur on an individual basis.
  • Mixtard 30/70 is administered subcutaneously in the abdominal wall, the upper arm, or the thigh. Injection sites should be rotated within the same region to reduce the risk of lipodystrophy and cutaneous amyloidosis. The duration of action of Mixtard30/70 may vary according to the dose, injection site, blood flow, temperature, and level of physical activity.
    Note: Diabetes MedsCheck with referral to healthcare team for education on injection technique and managing hypoglycaemia.

  • The safety and efficacy of Mixtard 30/70 has not been established in the elderly.

  • Hypoglycaemia
  • Hypersensitivity to insulin or any of the excipients
  • Insulin suspensions should not be administered intravenously
  • Insulin suspensions are not suitable for the treatment of diabetic ketoacidotic coma.

  • Hyperglycaemia - Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. The first symptoms of hyperglycaemia usually developed gradually, over a period of hours or days. They include nausea, vomiting, drowsiness, flushed dry skin, dry mouth, increased frequency of urination, thirst, and loss of appetite as well as acetone breath. Untreated hyperglycaemic events maybe life threatening.
    Note: Diabetes MedsCheck with referral to healthcare team for sick day management plan and education.
  • Hypoglycaemia: Hypoglycaemia is the most common adverse effect of insulins. As with all insulins, particular caution (including intensified blood glucose monitoring) should be exercised in individuals who are at greater risk of clinically significant sequelae from hypoglycaemic episodes.
    Note: Diabetes MedsCheck with counselling on side effect profile, including hypoglycaemia being part of the side effect profile. If happening regularly consider referral to healthcare for dose adjustment. Referral to healthcare team for managing hypoglycaemia and blood glucose monitoring. Regular blood glucose monitoring is essential in individuals on intensive insulin therapy and when there is a change in insulin type or dose.
  • Travelling with insulin: Before travelling between different time zones, an individual should be advised to consult their doctor or CDE, since this may mean that extra education may be needed due to different time zones.
    Note: Diabetes MedsCheck with referral to healthcare team for guidance.

  • Hypoglycaemia: Hypoglycaemia is the most common adverse effect of insulins. As with all insulins, particular caution (including intensified blood glucose monitoring) should be exercised in individuals who are at greater risk of clinically significant sequelae from hypoglycaemic episodes. These include (but are not restricted to) change in the injection area improved insulin sensitivity (e.g., by removal of stress factors, weight loss); unaccustomed, increased, or prolonged physical activity. intercurrent illness (e.g., vomiting, diarrhoea); inadequate food intake; missed meals; and alcohol consumption.
    Note: Diabetes MedsCheck with counselling on hypoglycaemia and referral to healthcare team for education on managing hypoglycaemia.
  • A marked change in glycaemic management l can cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens. As with all insulin regimens, intensification of insulin therapy with abrupt improvement in glycaemic management maybe associated with temporary visual impairment or worsening of diabetic retinopathy. However, long-term improved glycaemic management decreases the risk of progression of diabetic retinopathy.
    Note: Diabetes MedsCheck with education and referral to healthcare team.
  • Injection site and allergic reactions: As with any insulin therapy, lipodystrophy may occur at the injection site and delay insulin absorption. Other injection site reactions with insulin therapy include redness, pain, itching, hives, swelling and inflammation.
    Note: Diabetes MedsCheck with education on side effects and referral to healthcare team to establish correct injection technique.
  • Immune system disorders: Immediate type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angioedema, bronchospasm, hypotension, and shock, and maybe life threatening.
    Note: Diabetes MedsCheck with counselling on side effect profile, what to look and referral to hospital if allergic reaction occurs.

  • Mixtard 30/70 is an intermediate-acting insulin preparation. Its hypoglycaemic effect after subcutaneous administration begins after approximately 0.5 hour, is maximal between 2 and 12 hours and terminates after approximately 24 hours. Mixtard 30/70 is not exactly equivalent to its component insulins.
For more information on Mixtard 30/70, please see https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02733-3